Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 ± carboplatin vs investigator’s choice platinum doublet chemotherapy in recurrent epithelial ovarian cancer
CTR20240254Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tizetatug rezetecan in epithelial ovarian cancer (EOC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jan 2024; status: active.
02
Drugs
tizetatug rezetecan
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on CTR20240254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240254.